Notably, the combination of AP-1 and ALK5 inhibitors on resistant BCC cells did not result in any additional effect on Gli1 expression or cell viability, suggesting that these pathways may be redundant or acting upstream of a shared pathway (Supplementary Fig. 3f). This evidence concerns the gene FOSB and skin basal cell carcinoma.